Stock Ratings / Health Care / SNN / insiders

ALGN (66) ZBH (71) STE (72) MSA (72) ⌘ Pro Terminal →

Smith & Nephew SNATS Inc. (SNN) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$29.70 -2.33% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $29.52

Smith & Nephew SNATS Inc. (SNN) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $12.73B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SNN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SNN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Smith & Nephew SNATS Inc. (NYSE: SNN) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $29.70 (-2.33% 1D, market cap $12.73B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, SNN ranks #194 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SNN compare to ALGN and ZBH in the Health Care sector?

▼

Within the Health Care sector (Industrial Specialties), SNN carries a Roarable D+ (58/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, ALGN (Align Technology Inc.) holds a C+ grade (66/100 RQD, P/E 26.6x, ROIC 11.1%, cap $10.92B) and ZBH (Zimmer Biomet Holdings Inc.) posts a B- grade (71/100 RQD, P/E 26.4x, ROIC 4.6%, cap $18.59B). Among the 5-stock peer group, MSA leads on earnings multiple (24.8x) while MSA leads on capital efficiency (16.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SNN?

▼

For Smith & Nephew SNATS Inc. (SNN), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs. and sector rank #194 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $29.52 (-0.61%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY • 52.7% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE+0% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SNN)Realized 20D OHLCV Swing Band: ±3.3%

Deterministic 5-Pillar Attribution (58/100 Composite)

🔍 WHY SNN SCORES 58/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (28% of score)

Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+12/20 pts (21% of score)

SEC Form 4 / 13F Thermometer: 60% Net Buy • Cannibal Buyback (-1.24% YoY Shares)

▼ #1 Drag / Risk Factor: Macro Regime Fit8/20 pts (-12 pt drag)

Macro rate sensitivity & RSI-14 (63.6) create a -12 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$27.86+5.2% Next Q

Q2 (-2Q)

Grade C-$29.32+2.7% Next Q

Q3 (-1Q)

Grade C$30.10-1.3% Next Q

Current

Grade D+$29.70+0% Hist 90D α

Trajectory: C- (50) → D+ (58)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the SNN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 58/100 (D+) score, SNN faces multiple-compression risk if 32.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($28.35) or 200D SMA ($31.04) invalidates the momentum regime and cuts Target Base ($29.70) toward Bear Floor ($23.17).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SNN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SNN Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 58%NO 42%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

SNN Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (SNN)

No recent open-market Form 4 cluster sales or emergency dumps flagged on SNN. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SNN)

✓Walkthrough of SNN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SNN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -3.88%📐 HORIZONTAL RANGE

2026-11-02O $30.12H $30.41L $29.70C $29.70VOL 1.57M

RES: $31.33SUP: $24.62SMA50: $28.35SMA200: $31.04

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SNN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SNN Butterfly Map → + Track SNN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

25.3%/yr Implied 5Y Growth

vs. +6.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SNN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SNN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SNN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SNN)

Health Care Rank #194 of 1016 ⚔️ ALGN vs SNN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SNN vs. ALGN, ZBH, STE, MSA)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Smith & Nephew SNATS Inc. (SNN) ranks #194 by composite RQD confidence (58/100, grade D+) and #89 by equity capitalization ($12.73B). Within this direct 5-issuer industry benchmark cohort, MSA leads on earnings valuation at 24.8x trailing P/E, while MSA leads on capital efficiency and profitability with 16.6% ROIC and 46.5% gross margin. STE currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with SNN at 58/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SNN ACTIVE Smith & Nephew SNATS Inc.	D+	58/100	32.8x	—	9.9%	-2.33%	$12.73B	Benchmark Subject
ALGN Align Technology Inc.	C+	66/100	26.6x	67.2%	11.1%	-2.48%	$10.92B	/algn-vs-snn →
ZBH Zimmer Biomet Holdings Inc.	B-	71/100	26.4x	69.7%	4.6%	-3.03%	$18.59B	/zbh-vs-snn →
STE STERIS plc (Ireland)	B	72/100	28.9x	44.2%	10.1%	-2.16%	$22.63B	/ste-vs-snn →
MSA MSA Safety Incorporated	B	72/100	24.8x	46.5%	16.6%	-0.33%	$6.91B	/msa-vs-snn →

2. SNN Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Smith & Nephew SNATS Inc. (SNN) operates in Industrial Specialties (Health Care) with an equity capitalization of $12.73B, trailing P/E of 32.8x, forward P/E of 30.5x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 8/9.

3. SNN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SNN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SNN compare to ALGN and ZBH in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SNN?

Where is SNN trading relative to its 50-day, 200-day, and 52-week technical levels?

SNN last traded at $29.70 (-2.33% on volume of 1,730,165 shares), positioning the stock +4.76% above its 50-day simple moving average ($28.35) and -4.32% below its 200-day simple moving average ($31.04). Across its 52-week range of $26.12 to $37.09, SNN sits at the 32.6% percentile with a 14-day RSI of 63.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±3.3% ($28.72 to $30.68).

SNN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are SNN insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies SNN leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: SNN RQD Cockpit SNN 12M Forecast SNN Earnings & Move SNN Dividends & DRIP SNN Insiders & 13F SNN Whale Options SNN Profit Sankey SNN News & Why

Sector Peer Dials

Compare →

ALGN C+

Align Technology Inc.

66 /100

ZBH B-

Zimmer Biomet Holdings Inc.

MSA Safety Incorporated

72 /100

EW B+

Edwards Lifesciences Corporation

79 /100

ESTA E

Establishment Labs Holdings Inc.

30 /100

SNN Core Snapshot

Market Cap $12.73B

Trailing / Fwd P/E 32.8x / 30.5x

Gross Profit Margin —

Return on Capital (ROIC) 9.9%

Free Cash Flow Yield 2.21%

12M Base Price Target $29.70

FREE TRADER TOOLS

Own SNN Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With SNN → 🏆 Trade SNN in $100K Prop Arena →

SNN Wire

Why It Moved →

Peer / Ecosystem Wire Yahoo Finance • 7h ago

Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets

Direct Company Event Stock Traders Daily • 10h ago

Discipline and Rules-Based Execution in SNN Response

Direct Company Event https://www.dars.gov.et/ • 13h ago

Smith & Nephew (SNN) Holds Near $30.83 as Traders Eye Support at $29.29 - Up Down Volume

Peer / Ecosystem Wire MarketBeat • 16h ago

Top Teleflex (TFX) Competitors 2026

Direct Company Event www.siam.in • 19h ago

After +2.19% Gain, Is Smith (SNN) Still a Value Play? 2026-10-22 - Tick Index

ROARABLE RATING BRIEF • RQD 58/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SNN — Smith & Nephew SNATS Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:10:08Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, SNN scores 58 out of 100, graded D+, with the verdict "Roarable Sell — Weak Fundamentals / Trim." The five pillars are: Fundamental Cash Engine at 11 / 20 (ROIC 9.9%; FCF yield 2.21%), Whale 13F Flow at 11 / 20 (institutional accumulation and options positioning), Insider Conviction at 12 / 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 8 / 20 (Beta 1.03; sector sensitivity), and Forensic Balance Sheet at 16 / 20 (Altman Z 3.74; Piotroski F 8/9; Debt/Equity 0.39). The strongest pillar is the forensic balance sheet, which indicates low measured balance-sheet risk. The weakest are macro regime fit and the cash engine: the rating's own inputs show a modest ROIC and a thin free-cash-flow yield relative to a P/E (TTM) of 32.8, meaning the valuation leaves limited cushion if cash generation does not expand. Insider and institutional pillars are mid-range and do not offer a clear counterweight in the supplied data. For a prospective investor, the evidence points to a financially sound issuer priced at a premium multiple, where upside depends on earnings and cash-flow growth that the rating does not confirm. This is an analytical summary of the rating's components, not personalized financial advice.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
30.41	$12.73B	32.8	30.5	21	0.93	0%	1.03	$26.12 - $37.09	9.9%

Recent Catalysts & News Wire Analysis

Per the recent news section, six items were reported, with signal labels as follows:

CATALYST (GREEN): a report covering SNN market action, institutional positioning, and fundamental catalysts.
RISK WATCH (RED): a report titled around disciplined, rules-based execution in response to SNN.
MARKET WIRE (YELLOW): four items, covering a CARTIHEAL implant launch across European markets, a technical-level price report referencing $30.83 and $29.29, a competitor listing for Teleflex, and a report on a new USD 700 million bond reshaping the debt profile.

The bond item is the most fundamentally relevant headline, since it bears on the balance-sheet pillar, but the headline alone does not state terms, maturities, or use of proceeds. Several items have weak source attribution (one labeled with a government domain, one with a generic site name), so they should be treated as unverified. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are recorded.

Open Questions

What are the company's revenue, operating income, net income, and free cash flow across reported periods? The financials section is empty, so the earnings trajectory behind the 32.8 TTM P/E cannot be verified.
What are the terms, maturity, and use of proceeds for the reported USD 700 million bond, and how does it change leverage?
Why is gross margin reported as 0%, and is that a data gap or an accounting presentation issue?
What is the consensus analyst rating and price target, given that the analyst section is empty?
Who are the institutional and insider holders, and what is the direction of their recent activity, given that the holders section is empty?

SNN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Smith & Nephew SNATS Inc. (SNN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SNN Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 7h ago

Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets

Yahoo Finance report covering Smith & Nephew SNATS Inc. (SNN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Stock Traders Daily • 10h ago

Discipline and Rules-Based Execution in SNN Response

Stock Traders Daily report covering Smith & Nephew SNATS Inc. (SNN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 13h ago

Smith & Nephew (SNN) Holds Near $30.83 as Traders Eye Support at $29.29 - Up Down Volume

https://www.dars.gov.et/ report covering Smith & Nephew SNATS Inc. (SNN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 16h ago

Top Teleflex (TFX) Competitors 2026

MarketBeat report covering Smith & Nephew SNATS Inc. (SNN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST www.siam.in • 19h ago

After +2.19% Gain, Is Smith (SNN) Still a Value Play? 2026-10-22 - Tick Index

www.siam.in report covering Smith & Nephew SNATS Inc. (SNN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 22h ago

Smith & Nephew stock steadies as new USD 700 million bond reshapes its debt profile

ad-hoc-news.de report covering Smith & Nephew SNATS Inc. (SNN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 1d ago

(SNN) and the Role of Price-Sensitive Allocations

Stock Traders Daily report covering Smith & Nephew SNATS Inc. (SNN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Top MiniMed Group (MMED) Competitors 2026

MarketBeat report covering Smith & Nephew SNATS Inc. (SNN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SNN Bull vs. Bear Conversation Board — What's Your Call at $29.70?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SNN 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $32.84 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is SNN (D+ • RQD 58/100) a Buy at $30.41?

Welcome to the SNN (Smith & Nephew SNATS Inc.) Roar Pit. Current RQD Composite is 58/100 (Roarable Sell — Weak Fundamentals / Trim) in Industrial Specialties. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (32.8x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $25.24 (-17.0%)

Spot @ $30.41

Pump the brakes on SNN — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on SNN, but look at what you are paying: 32.8x trailing P/E with tightening sector spreads. Unless Smith & Nephew SNATS Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $34.97 (+15.0%)

Spot @ $30.41

SNN cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on SNN, the market is fixating on short-term headline noise in Industrial Specialties and ignoring the balance sheet and cash flow trajectory. At $30.41 (52-wk range $26.12 - $37.09), any beat on forward guidance forces shorts and underweight funds to chase.